strong growth solid data
top bottom line beat guidanc up
report revenu consensu estim driven
strensiq beat vs consensu soliri met consensu note
soliri continu grow double-digit adjust
enrol item bottom line beat estim vs consensu
driven lower expect expens also updat revenu guidanc
includ soliri metabol
franchis revenu compani expect tax rate adjust ep
guidanc rais adjust ep
accordingli reiter buy averag growth strong mg launch
gmg launch continu impress
launch soliri gener myasthenia gravi gmg strong
gate treat patient march total patient
enrol onesourc system expect current trajectori continu
supplement strong underli growth deliv soliri pnh ahu
strensiq see potenti upsid compani guidanc gmg launch continu
trajectori rest
also report posit top-line result phase switch studi
paroxysm nocturn hemoglobinuria pnh demonstr non-inferior
soliri lactat dehydrogenas ldh reduct well four key secondari
endpoint numer result favor endpoint
narrowli miss superior ldh reduct note power
demonstr saw breakthrough hemolysi compar soliri
meningococc infect observ either arm given posit phase
data switch studi expect file approv us eu
mid-year follow japan although statist superior
phase trial believ numer lower incid breakthrough
hemolysi facilit reimburs hemolysi expens manag
net dbt
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biotechnolog compani market
soliri monoclon antibodi therapi
treatment ultra-rar diseas includ
paroxysm nocturn hemoglobinuria pnh
compani also market strensiq treatment
hypophosphatasia kanuma lal-d
focu sever life threaten ultra rare
rate buy expect industri
growth compani market product soliri
success launch new product
strensiq kanuma see upsid risk street
estim addit pipelin
momentum creat news flow
price object base discount cash flow analysi use
wacc termin growth rate
downsid risk failur meet expect soliri sale and/or launch
strensiq asfotas alfa kanuma lal-d govern drug price
focu ultra-orphan product failur advanc key pipelin product includ
soliri new indic
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
